Zobrazeno 1 - 10
of 223
pro vyhledávání: '"Heinrich Wolf"'
Autor:
Nicola Giesen, Elena Busch, Enrico Schalk, Gernot Beutel, Maria M. Rüthrich, Marcus Hentrich, Bernd Hertenstein, Hans H. Hirsch, Meinolf Karthaus, Yascha Khodamoradi, Philipp Koehler, William Krüger, Michael Koldehoff, Robert Krause, Sibylle C. Mellinghoff, Olaf Penack, Michael Sandherr, Ruth Seggewiss-Bernhardt, Karsten Spiekermann, Rosanne Sprute, Jannik Stemler, Florian Weissinger, Bernhard Wörmann, Hans-Heinrich Wolf, Oliver A. Cornely, Christina T. Rieger, Marie von Lilienfeld-Toal
Publikováno v:
European Journal of Cancer. 181:102-118
The novel coronavirus SARS-CoV-2 and the associated infectious disease COVID-19 pose a significant challenge to healthcare systems worldwide. Patients with cancer have been identified as a high-risk population for severe infections, rendering prophyl
Autor:
Dietger Niederwieser, Thomas Lang, Rainer Krahl, Thomas Heinicke, Georg Maschmeyer, Haifa Kathrin Al-Ali, Sebastian Schwind, Madlen Jentzsch, Michael Cross, Christoph Kahl, Hans-Heinrich Wolf, Herbert Sayer, Antje Schulze, Peter Dreger, Ute Hegenbart, Alwin Krämer, Christian Junghanss, Lars-Olof Mügge, Detlev Hähling, Carsten Hirt, Christian Späth, Norma Peter, Bernhard Opitz, Axel Florschütz, Kolja Reifenrath, Niklas Zojer, Sebastian Scholl, Wolfram Pönisch, Simone Heyn, Vladan Vucinic, Andreas Hochhaus, Carlo Aul, Aristoteles Giagounidis, Leopold Balleisen, Bernd Oldenkott, Peter Staib, Michael Kiehl, Wolfgang Schütte, Ralph Naumann, Hartmut Eimermacher, Bernd Dörken, Cristina Sauerland, Eva Lengfelder, Wolfgang Hiddemann, Bernhard Wörmann, Carsten Müller-Tidow, Hubert Serve, Christoph Schliemann, Rüdiger Hehlmann, Wolfgang E. Berdel, Markus Pfirrmann, Utz Krug, Verena S. Hoffmann
Publikováno v:
Annals of Hematology. 102:547-561
A randomized inter-group trial comparing more intensive treatment strategies to a common standard arm 3 + 7 (CSA) was conducted in patients with non-M3 AML. Untreated patients ≥ 60 years were allocated to the CSA (n = 132) or to the study group arm
Publikováno v:
2022 44th Annual EOS/ESD Symposium (EOS/ESD).
Autor:
HEINRICH, WOLF-DIETER1 wolf-dieter.heinrich@mfn-berlin.de, MAUL, LUTZ CHRISTIAN2 lmaul@senckenberg.de
Publikováno v:
Fossil Imprint. 2020, Vol. 76 Issue 1, p40-58. 19p.
Autor:
Hans-Heinrich Wolf, Michael Cross, Kolja Reifenrath, Detlev Hähling, Rainer Krahl, Georg Maschmeyer, Thomas Fischer, Späth Christian, Christoph Kahl, Dietger Niederwieser, Christian Junghanss, Schmidt Volker, Antje Schulze, Thomas Heinicke, Niklas Zojer, Herbert G. Sayer, Haifa Kathrin Al-Ali, Axel Florschütz, Norma Peter, Andreas Hochhaus, Sebastian Scholl, Ute Hegenbart
Publikováno v:
Annals of Hematology
Ann Hematol
Ann Hematol
Relapse of acute leukemia is a frequent complication with uncertain outcome and poorly defined risk factors. From 1621 patients entered into two prospective clinical trials (AML02; n = 740 and AML04; n = 881), 74.2% reached complete remission (CR) 1
Autor:
Karin Mayer, Silke Neumann, Hans-Heinrich Wolf, Luisa Durán Graeff, Michael Sandherr, Annika Y. Classen, Stefan W. Krause, Larissa Henze, Olaf Penack, Maximilian Christopeit, Georg Maschmeyer, Jörg Janne Vehreschild, Nael Alakel, Oliver A. Cornely, Marie von Lilienfeld-Toal, Florian Weißinger
Publikováno v:
Annals of Hematology
Hematologic and oncologic patients with chemo- or immunotherapy-related immunosuppression are at substantial risk for bacterial infections and Pneumocystis jirovecii pneumonia (PcP). As bacterial resistances are increasing worldwide and new research
Autor:
Christian Straka, Peter Liebisch, Hans Salwender, Burkhard Hennemann, Bernd Metzner, Stefan Knop, Sigrid Adler-Reichel, Christian Gerecke, Hannes Wandt, Martin Bentz, Tim Hendrik Bruemmendorf, Marcus Hentrich, Michael Pfreundschuh, Hans-Heinrich Wolf, Orhan Sezer, Ralf Bargou, Wolfram Jung, Lorenz Trümper, Bernd Hertenstein, Else Heidemann, Helga Bernhard, Nicola Lang, Norbert Frickhofen, Holger Hebart, Ralf Schmidmaier, Andreas Sandermann, Tobias Dechow, Albrecht Reichle, Brigitte Schnabel, Kerstin Schäfer-Eckart, Christian Langer, Martin Gramatzki, Axel Hinke, Bertold Emmerich, Hermann Einsele
Publikováno v:
Haematologica, Vol 101, Iss 11 (2016)
Autologous transplantation is controversial for older patients with multiple myeloma. The role of age-adjusted high-dose melphalan and the impact of induction chemotherapy cycles is still unclear. A total of 434 patients aged 60–70 years were rando
Externí odkaz:
https://doaj.org/article/8484c26faddc436abed9f7a934ff997e
Publikováno v:
IEEE Transactions on Device and Materials Reliability. 19:591-601
This study analyzes the Electrostatic Discharge (ESD) susceptibility of a 28 nm high-speed CMOS Integrated Circuit (IC) for network applications (25 Gbps), showing a non-negligible failure rate in manufacturing after having passed Charged Device Mode
Autor:
Hans-Heinrich Wolf, Christian Langer, Heinz Dürk, Bernd Metzner, Hans Salwender, Wolfram Brugger, Wolfram Jung, Martin Gramatzki, Florian Bassermann, Monika Engelhardt, Hermann Einsele, Thomas M. Fischer, Herbert G. Sayer, Christian Straka, Wolf Rösler, Peter Liebisch, Stefan Knop, Martin Vogel, Jürgen Müller
Publikováno v:
European journal of haematologyREFERENCE. 107(5)
OBJECTIVE A post hoc subgroup analysis of two phase III trials (NCT00416273, NCT00416208) was carried out to investigate the influence of 100/140 and 200 mg/m² melphalan as well as single/double autologous stem cell transplantation (ASCT) on progres
Autor:
Christoph Meisner, Martin Kaufmann, Ralf Bargou, Thomas Fischer, Orhan Sezer, Norbert Frickhofen, Marcus Hentrich, Hermann Einsele, Donald Bunjes, Hans-Heinrich Wolf, Stephan Mielke, Christian Schmidt, Ernst Holler, Christian Straka, Martin Gramatzki, Bernd Hertenstein, Peter Liebisch, Mathias Freund, Wolfram Jung, Bernd Metzner, Dietrich Peest, Florian Bassermann, Martin Kropff, Christian Langer, Georg Hess, Monika Engelhardt, M. Svaldi, Lothar Kanz, Stefan Knop, Helmut Ostermann, Holger Hebart, Georg Maschmeyer
Publikováno v:
Leukemia. 33:2710-2719
This phase 3 trial compared tandem autologous stem cell transplantation (autoSCT) versus autoSCT followed by reduced-intensity conditioning allogeneic stem cell transplantation (auto/alloSCT) in patients with newly diagnosed multiple myeloma (MM) wit